Table 3 Treatment-related adverse events in 30 patients
Any grade | Grade 1–2 | Grade 3 | |
|---|---|---|---|
Any treatment-related AEs | 30 (100.0%) | 30 (100.0%) | 8 (26.7%) |
Lymphopenia | 27 (90.0%) | 23 (76.7%) | 4 (13.3%) |
Anaemia | 21 (70.0%) | 21 (70.0%) | 0 |
Hypoproteinemia | 21 (70.0%) | 21 (70.0%) | 0 |
Leukopenia | 16 (53.3%) | 16 (53.3%) | 0 |
Neutropenia | 13 (43.3%) | 12 (40.0%) | 1 (3.3%) |
Elevated AST | 10 (33.3%) | 9 (30.0%) | 1 (3.3%) |
Elevated ALT | 8 (26.7%) | 6 (20.0%) | 2 (6.7%) |
Thrombocytopenia | 7 (23.3%) | 6 (20.0%) | 1 (3.3%) |
Rash | 6 (20.0%) | 6 (20.0%) | 0 |
Pain | 5 (16.7%) | 5 (16.7%) | 0 |
Nausea | 5 (16.7%) | 5 (16.7%) | 0 |
Loss of appetite | 5 (16.7%) | 5 (16.7%) | 0 |
Abnormal feeling | 4 (13.3%) | 4 (13.3%) | 0 |
Itching | 4 (13.3%) | 4 (13.3%) | 0 |
Vomit | 4 (13.3%) | 4 (13.3%) | 0 |
Lower extremity venous thrombosis | 1 (3.3%) | 1 (3.3%) | 0 |
Immune-related AEs | 7 (23.3%) | 7 (23.3%) | 1 (3.3%) |
Hypothyroidism | 5 (16.7%) | 5 (16.7%) | 0 |
Guillain⁃Barré syndrome | 1 (3.3%) | 0 | 1 (3.3%) |
Hyperglycemia | 3 (10.0%) | 3 (10.0%) | 0 |
